Advertisement

Topics

Latest Top Pharmaceutical Companies in India NewsRSS

16:41 EDT 17th August 2018 | BioPortfolio

Dr. Reddy's Laboratories Ltd DRREDDY Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryDr. Reddy's Laboratories Ltd Dr. Reddy's is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, ...

Biocon Ltd BIOCON Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryBiocon Ltd Biocon is a global biopharmaceutical company specialized in biopharmaceuticals and research services. The company produces a wide range of active pharmaceutical ingredients APIs, branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies MAbs, rhInsulin and insulin analogs. Its core therapeutic areas include diabetes, cancer and autoim...

Cipla introduces generic Xeloda

FDA approves Cipla’s generic Reyataz

Dr. Reddy's Laboratories Ltd DRREDDY Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryDr. Reddy's Laboratories Ltd Dr. Reddy's is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, ...

Cadila Healthcare Ltd CADILAHC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryCadila Healthcare Ltd Cadila is an integrated, global healthcare provider. It discovers, develops, manufactures and markets various healthcare products. The company's product portfolio includes active pharmaceutical ingredients APIs, formulations, wellness and animal health products. Cadila's products find application in the treatment of disease related to gastrointestinal, cardiovascular, ...

Cipla Ltd CIPLA Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryCipla Ltd Cipla is a global pharmaceutical company which focuses on providing high quality affordable medicines. It researches, develops, manufactures and commercializes a wide range of pharmaceutical products including active pharmaceutical ingredients APIs, formulations and animal healthcare products. The company also offers overthecounter OTC products and a range of inhalation medication...

Glenmark Pharmaceuticals Receives FDA Acceptance Of Company's First New Drug Application For Ryaltris

News Ryaltris is an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older.

Zydus Cadila gets 2 FDA nods, 1 tentative

Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Exclusive license agreement potentially worth more than $120 million in addition to royalties GBR 1302 is a clinical stage, HER2xCD3 bispecific antibody generated from Glenmark’s proprietary BEAT™ (Bispecific Engagement of Antibodies based on the T cell receptor) technology platform Harbour BioMed and Glenmark P...

Torrent Pharmaceuticals Ltd TORNTPHARM Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummaryTorrent Pharmaceuticals Ltd Torrent manufactures and markets branded and unbranded generic pharmaceuticals. It provides products in cardiovascular, central nervous system, gastrointestinal, diabetology, antiinfective and pain management segments. Also, the company has presence in nephrology, cancer, gynecology and pediatric segments. Torrent has a fully equipped research center that is appr...

20182023 UK Capecitabine Market Report Status and Outlook [Report Updated: 13032018] Prices from USD $3360

In 2017, the Capecitabine market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include Roche Teva Mylan Hikma Hengrui Medicine Cipla Reliance Group HeteroSplit by product types/category, covering 500 mg 150 mgSplit by applications/end use industries, covers Breast Cancer ...

Global Insulin Therapeutics Market Segmented by Product Type, Drug Type, Disease, and Geography Growth, Trends, and Forecast 2018 2023 [Report Updated: 01032018] Prices from USD $4250

The global insulin therapeutics market is expected to register a CAGR of 8.0% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of diabetes and obesity in the region.Growing Obesity and Diabetes Prevalence, Especially in Developing CountriesDiabetes ranks among the fastgrowing chronic diseases in the United States; currently, diabetes affects ...

Lupin Ltd LUPIN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummaryLupin Ltd Lupin focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients APIs. The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastrointestinal, antiinfectives, NSAIDs, antiTB and cephalosporins. It undertakes extensive research and developme...

20182023 India Capecitabine Market Report Status and Outlook [Report Updated: 13032018] Prices from USD $3360

In 2017, the Capecitabine market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In India market, the top players include Roche Teva Mylan Hikma Hengrui Medicine Cipla Reliance Group HeteroSplit by product types/category, covering 500 mg 150 mgSplit by applications/end use industries, covers Breast C...

Cadila Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11072018] Prices from USD $250

SummaryCadila Pharmaceuticals Ltd Cadila Pharmaceuticals is a pharmaceutical company that develops, manufactures and distributes pharmaceutical products. Its products include active pharmaceutical ingredients API and pharmaceutical formulations. The company's products are in the form of capsules, tablets, orals, soft and hard gelatin capsules, and liquid solutions. Its business operations includes...

Indivior’s generic legal battle expedited by US court

The US Court of Appeals has expedited Dr. Reddyâs appeal against an injunction that aims to block generic sales of Suboxone Film, says Indivior.

Cipla Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Cipla Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Cipla Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Cipla Limited ...

Lupin launches generic Topicort, gets tentative OK for generic Cialis

Dr. Reddy's Laboratories Launches Hervycta In India

NewsDr. Reddy’s Laboratories has launched Hervycta, a biosimilar of Roche’s Herceptin, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer, and metastatic gastric cancer).

Dr. Reddy’s launches Herceptin biosimilar in India

Dr. Reddyâs Laboratories has announced its biosimilar version of Rocheâs Herceptin, Hervycta (trastuzumab), is now available on the Indian market.

Dr. Reddy’s Q1 FY19 Financial Results

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June 30, 2018 under International Financial Reporting Standards (IFRS).         ...

Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire

-- With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation -- Omeros Corporation (Nasdaq: OMER) today announced that its patent infringement lawsuit against Sandoz Inc. (Sandoz) concerning Sandoz’s Abbreviated New Drug Application (ANDA), which sought approval from the U.S. Food and Drug Administrati...

Dr. Reddy's Laboratories Announces the Launch of Hervycta® (trastuzumab biosimilar) in India

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) announced today that it has launched Hervycta® (trastuzumab), a biosimilar of Roche’s Herceptin®, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer). Dr. Reddy’s Hervycta® is available in stre...

Global Insulin Therapeutics Market Segmented by Product Type, Drug Type, Disease, and Geography Growth, Trends, and Forecast 2018 2023 [Report Updated: 01032018] Prices from USD $1923

The global insulin therapeutics market is expected to register a CAGR of 8.0% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of diabetes and obesity in the region.Growing Obesity and Diabetes Prevalence, Especially in Developing CountriesDiabetes ranks among the fastgrowing chronic diseases in the United States; currently, diabetes affects ...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in India market research data and corporate reports here